Anti-phosphatidylserine/prothrombin antibodies in patients with polyarteritis nodosa.

Anti-fosfatidilserina/protrombina Anti-phospatidylserine/prothrombin Anti-phospholipid antibodies Anticuerpos antifosfolípidos Poliarteritis nodosa Polyarteritis nodosa Vasculitis

Journal

Reumatologia clinica
ISSN: 2173-5743
Titre abrégé: Reumatol Clin (Engl Ed)
Pays: Spain
ID NLM: 101717526

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 12 05 2020
accepted: 27 05 2020
entrez: 10 11 2021
pubmed: 11 11 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Anti-phospatidylserine/prothrombin (aPS/PT) antibodies have been described in cutaneous Polyarteritis Nodosa (PAN) in association with specific manifestations. To determine aPS/PT antibodies in patients with PAN and its correlation with clinical manifestations. Cross-sectional comparative study including PAN patients and 20 controls (10 Microscopic Polyangiitis [MPA] and 10 Behçet's disease [BD]). Clinical and demographic variables, treatment, serologic markers, prognosis, activity and damage indexes were evaluated. aPS/PT, anti-cardiolipin (aCL), anti-beta 2 glycoprotein 1 (anti-B2GP1) antibodies, and lupus anticoagulant (LA) were determined. Fourteen patients with PAN were included, 11 (79%) women, with disease duration of 207 months, and mostly inactive disease. Only one patient with PAN and one with BD were positive for aPS/PT IgG. LA was the most frequent antibody identified. One patient with MPA and one with BD were positive for aCL IgM; one with MPA for anti-B2GP1 IgG, and one with PAN for anti-B2GP1 IgM. aPS/PT antibodies are not frequent in patients with longstanding inactive PAN.

Identifiants

pubmed: 34756313
pii: S2173-5743(21)00019-8
doi: 10.1016/j.reumae.2020.05.005
pii:
doi:

Substances chimiques

Antibodies, Antiphospholipid 0
Phosphatidylserines 0
Prothrombin 9001-26-7

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

521-524

Informations de copyright

Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Auteurs

Susy Marcela Sánchez-Cubías (SM)

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Eduardo Martín-Nares (E)

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Gabriela Hernández-Molina (G)

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Carlos A Nuñez-Alvarez (CA)

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Manuel Antonio Sedano-Montoya (MA)

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Angel Gabriel Vargas-Ruiz (AG)

Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Andrea Hinojosa-Azaola (A)

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address: andreaha@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH